Record Number of Bendamustine Abstracts Accepted for Presentation at the …SYS-CON Media (press release)Two oral and three poster presentations focus on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standard…
Record Number of Bendamustine Abstracts Accepted for Presentation at the …PR Newswire UK (press release)Two oral and three poster presentations focus on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standar…
Latest topics referred to NICE: October 2012dh.gov.ukTo appraise the clinical and cost effectiveness of rituximab in combination with corticosteroids within its licensed indication for the treatment of anti-neutrophil cytoplasmic antibody-associated va…
Scientists at Technion-Israel Institute of Technology Release New Data on …Equities.comOur news editors obtained a quote from the research from the Technion-Israel Institute of Technology, "Here, we utilize gold nanospheres conjugated to Rituxim…
Chugai in co-development accord for obinutuzumab with Nippon ShinyakuThe Pharma LetterGA101 is a glycoengineered type II anti-CD20 monoclonal antibody created by GlycArt AG and is a compound that selectively targets the CD20 protein on B-cells, the sam…
NIPPON SHINYAKU CO. LTD. : Co-Development and Co-Marketing Agreement …4-tradersGA101 is a glycoengineered type II anti-CD20 monoclonal antibody created by GlycArt AG and is a compound that selectively targets the CD20 protein on B-cells, same as ritu…
CHUGAI PHARMACEUTICAL CO., LTD. : Co-Development and Co-Marketing …4-tradersGA101 is a glycoengineeredtype II anti-CD20 monoclonal antibody created by GlycArt AG and is a compound that selectively targets the CD20 protein on B-cells, same as rituxima…
Liposomal doxorubicin inferior for AIDS-related lymphomaModernMedicine"I think it's fair to say the regimen was not as effective as we hoped it would be, and it's probably not as effective as R-EPOCH," that is, etoposide, prednisone, …
Rituximab may help patients with aPL-related clinical problemsNews-Medical.netRituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not resp…
Rituximab shows promise for clinical problems tied to antiphospholipid antibodiesScience CodexRituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems …